Brand Reference: Lodoco, Colcrys
| Metric | Verified Benchmark | Source |
|---|---|---|
| Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory) RxNorm Concept ID | 2683 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2400 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $118.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $9.20 / mo | Cost Plus Drugs Wholesale Feed |
| Community Mean Out-of-Pocket Paid | $12.00 / mo | 22 Zero-PHI Verified Patient Logs |
Binds unpolymerized beta-tubulin inside neutrophils and coronary plaque macrophages to prevent microtubule assembly and NLRP3 inflammasome activation by cholesterol crystals—cutting IL-1beta, IL-18, and hs-CRP to reduce recurrent MACE events by 31% (LoDoCo2 / COLCOT trials).
Out-of-pocket price dispersion on Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory) spans $9.20 to $118.00 per 30-day fill: pharmacy acquisition benchmarks sit near $0.2400/unit, allowing cash buyers bypassing PBM spread pricing to retain $108.80 each month (92% reduction).
With 27–31 hours (concentrates 16-fold inside leukocytes) residence kinetics and 45% oral bioavailability, Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory) undergoes intestinal/hepatic cyp3a4 demethylation and p-glycoprotein biliary efflux and establishes therapeutic activity over 12–24 hours neutrophil chemotaxis suppression; 4 weeks hs-crp drop.
Standard adult regimens span 0.5 mg PO once daily (Lodoco coronary plaque stabilization), 0.6 mg PO once daily. Prescribers screen specifically against concomitant strong cyp3a4 or p-gp inhibitors (clarithromycin/cyclosporine) in renal or hepatic impairment; egfr < 30 ml/min, while community micro-logs most frequently note week-1 loose stools (21% of reports), mild abdominal cramping (11% of reports).
Across 22 verified cash-pay logs, Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory) achieves a 89.90% Worth-It rating with out-of-pocket spend averaging $12.00/mo versus $118.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Cost Plus Drugs at 0.5 mg PO once daily (Lodoco coronary plaque stabilization) for Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory); monthly out-of-pocket dropped to $8.10 compared with $118.00 retail.
Completed 10 weeks on Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory) (0.6 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 0.5 mg PO once daily (Lodoco coronary plaque stabilization) Low-Dose Colchicine (0.5–0.6 mg Vascular Anti-Inflammatory) sourced via Cash Clinic ($10.67/mo cash pay without insurance prior authorization).